Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $62.3852W HIGH $94.16
Volume
1.29 M
Value Traded
119.14 M
Short % Float
3.36%
-1.64%Week
-4.02%1 Month
+12.66%3 Month
+31.34%6 Month
-7.61%5 Year
-7.61%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
14.71 B
EPS (TTM)
8.42
P/E Ratio
10.26
Ent. Value
18.88 B
Total Shares
170.22 M
Float Shares
144.58 M
Insiders
15.06%
Institutions
76.60%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
SOLV Catalyst Timeline
Dated clinical, regulatory and corporate events for Solventum Corporation
Past FDA Catalysts and PDUFA Decisions
How SOLV actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2023-01-20 | Soluprep S (chlorhexidine gluconate) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D39 / 100
Pipeline Score
$790M
Pipeline Value
Not rated
Valuation Signal
5
Drugs Scored
-
rNPV / MCap
Top 42%
Mid Cap(rank 277 of 658)
Percentile Rank
Solventum Corporation faces pipeline headwinds (39/100), with $929M risk-adjusted pipeline value, led by ChloraPrep Hi-Lite Orange in Bacterial Reduction on Skin Flora Post-product Application (Phase 3).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ChloraPrep Hi-Lite Orange Small moleculeCompletedNCT01968707 | Bacterial Reduction on Skin Flora Post-product Application | Phase 3 | COMPLETED | 426 | Jun 1, 2014 |
Clinical Trial Results
Readouts, endpoints and source filings for every SOLV program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Hanson Bryan CDirector, Officer (Chief Executive Officer) | Option | 67,261 211,983 held | $0.00 | 09/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in SOLV
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| ORBIMED ADVISORS LLC | 0.1 % (-50 %) | 4.83 M | 69.30 K | -65.35% ( -130.70 K) |
SOLV Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How SOLV ranks across every disease it competes in
Competitive Position is a premium feature
See how SOLV ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialSOLV News
-SOLV
Sep 2, 2026Solventum to Participate in the 2026 Wells Fargo Healthcare Conference
Solventum will participate in the Wells Fargo Healthcare Conference on September 9, 2026. The company's management will engage in a fireside chat, providing insights into their innovations in healthcare. A live and archived replay of the discussion will be accessible on their website, enhancing investor engagement.
Read more →-SOLV
Aug 5, 2026▼ -5.2%on this news
Solventum Reports Second Quarter 2026 Financial Results
Solventum reported its second quarter 2026 financial results, showing a 2.2% increase in sales and a notable 9.5% rise in organic sales. The company announced plans to separate its Health Information Systems segment to enhance focus on MedTech. Additionally, Solventum raised its full-year guidance for organic sales growth and adjusted EPS, reflecting strong operational execution despite a decline in net income.
Read more →-SOLV
Aug 5, 2026▼ -5.2%on this newsshared move
Solventum Announces Intent to Separate its Health Information Systems Business
Solventum announced plans to separate its Health Information Systems business to enhance its focus as a MedTech company. This strategic move aims to maximize shareholder value and enable targeted investments in both businesses. The separation is part of a broader transformation strategy and is expected to be completed within 12 to 18 months.
Read more →-SOLV
Jul 15, 2026Solventum to Report Second Quarter Fiscal 2026 Earnings on August 5, 2026
Solventum (NYSE: SOLV) will announce its second quarter fiscal 2026 earnings on August 5, 2026, after market close. A webcast will follow the release for management to discuss the results and other relevant information. Interested parties can access the webcast through Solventum's investor relations website.
Read more →-SOLV
May 27, 2026Solventum to Participate in the 2026 Jefferies Healthcare Conference
Solventum announced its participation in the Jefferies Healthcare Conference scheduled for June 3, 2026. The management will engage in a fireside chat at approximately 9:55 a.m. EDT in New York. A live and archived replay of the chat will be accessible on the company's investor website.
Read more →-SOLV
May 14, 2026Solventum Foundation and America's ToothFairy Launch National Effort to Expand Access to Preventive Dental Care
The Solventum Foundation has announced a $350,000 grant to America's ToothFairy aimed at expanding access to dental care for underserved communities. This initiative will provide oral health screenings, education, and fluoride treatments to over 100,000 children and caregivers. Additionally, Solventum's dental business will donate fluoride treatments and engage employees in community support activities.
Read more →-SOLV
May 7, 2026Solventum to Participate in the 2026 BofA Securities Health Care Conference
Solventum (NYSE: SOLV) will participate in a fireside chat at the BofA Securities Health Care Conference on May 13, 2026. The event will take place at 10:00 a.m. PDT in Las Vegas, NV. The company aims to highlight its innovative healthcare solutions and engage with stakeholders during this prominent event.
Read more →-SOLV
May 5, 2026Solventum Reports First Quarter 2026 Financial Results
Solventum reported its first quarter financial results for 2026, showing a 3.0% decrease in reported sales but a 2.1% increase in organic sales. The adjusted diluted earnings per share rose by 10.6%, and the company affirmed its full-year guidance for organic sales growth. However, both operating cash flow and free cash flow were negative, reflecting ongoing challenges.
Read more →-SOLV
Apr 14, 2026Solventum to Report First Quarter Fiscal 2026 Earnings on May 5, 2026
Solventum (NYSE: SOLV) will announce its first quarter fiscal 2026 earnings on May 5, 2026, after market close. A webcast will follow the earnings release for management to discuss the results and other relevant information. The company aims to enhance healthcare through innovative solutions.
Read more →-SOLV
Mar 11, 2026Solventum to Participate in the 2026 KeyBanc Healthcare Forum
Solventum announced its participation in a virtual fireside chat at the KeyBanc Healthcare Forum on March 18, 2026. This event will allow the company to engage with investors and discuss its innovative approaches to healthcare. More details about the event will be available on their investor relations website.
Read more →-SOLV
Feb 26, 2026Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance
Solventum reported its fourth quarter 2025 financial results, revealing a 3.7% decrease in reported sales despite a 3.5% increase in organic sales. The net income for the year rose significantly by 224.8%, and the company provided guidance for 2026, projecting organic sales growth of 2.0% to 3.0%. However, challenges persist, with a notable decline in free cash flow of 64.1% in the fourth quarter. The CEO emphasized the company's ongoing transformation and commitment to achieving long-term goals.
Read more →-SOLV
Dec 24, 2025Solventum Completes Acquisition of Acera Surgical
Solventum has finalized its acquisition of Acera Surgical, a company specializing in engineered materials for regenerative wound care. This acquisition, valued at $725 million with additional contingent payments, aims to enhance Solventum's wound care offerings. The CEO emphasized the strategic importance of this move in their transformation plan, which is expected to benefit patients and shareholders alike.
Read more →-SOLV
Dec 17, 2025Global Expert Panel Publishes New Recommendations on Advanced Use of Closed Incision Negative Pressure Therapy
Solventum announced new consensus recommendations from an international panel regarding closed incision negative pressure therapy (ciNPT) using reticulated open cell foam (ROCF) dressings. These guidelines emphasize the therapy's evolving role in enhancing patient safety and improving surgical outcomes across various procedures. The recommendations highlight specific risk factors for ciNPT use and aim to standardize practices for at-risk surgical patients.
Read more →-SOLV
Dec 16, 2025Solventum Earns Diamond Level HIRC Resiliency Badge, Demonstrating Best-In-Class Supply Chain Strength
Solventum has earned the Diamond Level Resiliency Badge from the Healthcare Industry Resilience Collaborative, marking the highest recognition for supply chain strength in healthcare. This certification reflects the company's capability to deliver critical healthcare products consistently, even amid supply disruptions. The achievement highlights Solventum's commitment to operational excellence and patient care continuity.
Read more →-SOLV
Nov 20, 2025Solventum Announces $1 Billion Share Repurchase Program
Solventum has announced a $1 billion share repurchase program approved by its Board of Directors. This initiative aims to enhance shareholder value and reflects the company's robust financial health and strategic growth plans, including the recent acquisition of Acera Medical. Share repurchases are expected to commence in 2026, subject to market conditions.
Read more →-SOLV
Nov 20, 2025Solventum Announces Agreement to Acquire Acera Surgical
Solventum has announced its agreement to acquire Acera Surgical for $725 million, with potential additional payments based on future milestones. This acquisition is aimed at enhancing Solventum's MedSurg portfolio, particularly in the synthetic tissue matrices market. Acera's innovative products are expected to generate approximately $90 million in sales in 2025, with the deal anticipated to create significant value for stakeholders.
Read more →-SOLV
Nov 6, 2025Solventum Reports Third Quarter 2025 Financial Results
Solventum has reported its third quarter financial results for 2025, showing a 0.7% increase in total sales and a 2.7% rise in organic sales. The company has raised its full-year guidance for organic sales growth and adjusted earnings per share outlook, reflecting positive momentum across all business segments. However, challenges persist with a significant decline in operating cash flow and negative free cash flow, alongside a decrease in operating income margins attributed to tariffs and costs related to growth initiatives. The new 'Transform for the Future' initiative is expected to enhance operational efficiency and generate considerable cost savings.
Read more →-SOLV
Nov 3, 2025Solventum to Participate in the 2025 Stifel Healthcare Conference
Solventum announced its participation in the Stifel Healthcare Conference scheduled for November 12, 2025. Executives will engage in a fireside chat, providing insights into the company's innovative healthcare solutions. The event will be accessible live and via replay on the company's website, emphasizing Solventum's commitment to transparency.
Read more →-SOLV
Sep 8, 2025Solventum Announces Pricing of its Upsized $2 Billion Note Tender Offers
Solventum has announced the pricing of its up to $2 billion note tender offers, aimed at repurchasing specific series of its outstanding notes. These offers reflect an increase in the Aggregate Cap and are designed to enhance the company's financial stability. The lead dealer managers for this initiative include major financial institutions like J.P. Morgan and Goldman Sachs. While the tender offer presents an opportunity for note holders, it excludes certain series, which may affect some investors.
Read more →-SOLV
Sep 8, 2025Solventum Announces Early Tender Results and Upsizing of its Note Tender Offers
Solventum announced early tender results for its note tender offers, increasing the Aggregate Cap to $2 billion. The company reported valid tenders exceeding the maximum amounts set for the offers. However, due to oversubscription, not all notes tendered will be accepted. The Financing Condition for the offers has been satisfied.
Read more →About Solventum Corporation
Headquarters1750 YANKEE DOODLE ROAD, EAGAN, MN, 55121
BIOPHARMAWATCH ELITE PLUS
Trade the next SOLV catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime